Statin Discontinuation Trial at ASCO

Discontinuing statins may benefit terminally ill patients: a RCT of statin discontinuation found no mortality difference, improved quality of life, and a moderate reduction in the cost of care according to abstracts presented at the  American Society of Clinical Oncology (ASCO) annual meeting. I am a part of the Palliative Care Research Cooperative (PCRC), a palliative care focused clinical trials cooperative group funded by the National Institute of Nursing Research (NINR),and the lead author of a manuscript that focuses on the cost and policy implications of this study.

We can’t say much more until the papers are published, but I want to leave you with this thought experiment:

  • imagine that in patients with less than 12, but more than 1 month life expectancy, that an RCT of a new drug showed no mortality impact, improved quality of life, and lead to modest cost reductions.

What would the policy discussion around that new drug look like?

About Don Taylor
Professor of Public Policy at Duke University (with appointments in Business, Nursing, Community and Family Medicine, and the Duke Clinical Research Institute). I am one of the founding faculty of the Margolis Center for Health Policy, and currently serve as Chair of Duke's University Priorities Committee (UPC). My research focuses on improving care for persons who are dying, and I am co-PI of a CMMI award in Community Based Palliative Care. I teach both undergrads and grad students at Duke. On twitter @donaldhtaylorjr

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: